Many of these gene flaws - there are plenty of them, with names like BCR-ABL - are relative newcomers to medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
A)medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
B)medical terminology like a majority of the new anti-tumor drugs that are still in early testing, and aimed at them.
C)medical terminology, as are a majority of the new anti-tumor drugs that are still in early testing, aimed at them.
D)medical terminology like a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
E)medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, and aimed at them.
OAA
Experts please explain and also i want to know as are is correct?
A)medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
B)medical terminology like a majority of the new anti-tumor drugs that are still in early testing, and aimed at them.
C)medical terminology, as are a majority of the new anti-tumor drugs that are still in early testing, aimed at them.
D)medical terminology like a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
E)medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, and aimed at them.
OAA
Experts please explain and also i want to know as are is correct?













